SavedAdd your journal

Journals / Haydarpaşa Numune Medical Journal / 2018 / Cilt: 58 - Sayı: 1

Rifaximin-induced Neutropenia in Patients with Cirrhosis

Ayça SALTÜRK
Can GÖNEN
Osman BEDİR
Pages
56–57
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This case is presented to highlight the fact that neutropenia can develop due to rifaximin use in patients with hepatic cirrhosis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Rifaximin is an antibiotic of the rifamycin family.
📊
Key Findings & Data:In patients with liver damage, however, the systemic effect increases as the severity of liver damage increases.
💡
Conclusion & Impact:This case is presented to highlight the fact that neutropenia can develop due to rifaximin use in patients with hepatic cirrhosis.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Rifaximin is an antibiotic of the rifamycin family. In healthy individuals, it is very poorly absorbed into the blood stream. In patients with liver damage, however, the systemic effect increases as the severity of liver damage increases. This case is presented to highlight the fact that neutropenia can develop due to rifaximin use in patients with hepatic cirrhosis.

🔖

Cite This Article

SALTÜRK, A., GÖNEN, C., BEDİR, O. (2018). Rifaximin-induced Neutropenia in Patients with Cirrhosis. Haydarpaşa Numune Medical Journal, Cilt: 58 - Sayı: 1, 56–57. https://ajindex.com/articles/215297

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (6)

  1. Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, et al. Hepatic Encephalopathy in Chronic Liver Disease: 2014 Practice Guideline by AASLD and EASL. Available at: https:// www.aasld.org/sites/default/files/guideline_documents/hepaticencephenhanced. pdf. Accessed Feb 16, 2018
  2. Riordan SM, Williams R. Treatment of hepatic encephalopathy. N Engl J Med 1997;337:473–9. [CrossRef ] 3. Robins GW, Wellington K. Rifaximin: a review of its use in the management of traveller's diarrhoea. Drugs 2005;65:1697–713
  3. Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010;362:1071–81. [CrossRef ] 5. Chitre MM, Berenson CS. Idiosyncratic rifabutin-induced leukopenia and SIADH: case report and review. Pharmacotherapy 2001;21:493–7. [CrossRef ] 6. van Assendelft AH. Leucopenia caused by two rifampicin preparations. Eur J Respir Dis 1984;65:251–8
  4. Descombe JJ, Dubourg D, Picard M, Palazzini E. Pharmacokinetic study of rifaximin after oral administration in healthy volunteers. Int J Clin Pharmacol Res 1994;14:51–6
  5. Xifaxan (rifaximin) product information. Morrisville, NC: Salix Pharmaceuticals; 2010 Nov. Available at: https://www.accessdata. fda.gov/drugsatfda_docs/appletter/2010/021361s009ltr. pdf. Accessed Feb 16, 2018
  6. Hynicka LM, Silva KN. Probable rifaximin-induced neutropenia. Am J Health Syst Pharm 2012;69:583–6. [CrossRef ]